Table 3.
Approved targeted therapies for GI cancer.
| GI cancer | Drug | Target |
|---|---|---|
| Gastric cancer | Trastuzumab | HER2 |
| Ramucirumab | VEGFR-2 | |
| Pembrolizumab | PD-1 | |
| Hepatocellular cancer | Sorafenib | RAF, VEGFR-2, VEGFR-3, PDGFR, c-KIT |
| Colon cancer | Cetuximab, panitumumab | EGFR |
| Bevacizumab | VEGF | |
| Regorafenib | VEGFR-1, VEGFR-2, VEGFR-3, BRAF, c-KIT, RET, PDGFR | |
| Colon cancer with MSI-H | Pembrolizumab | PD-1 |
HER2, human epidermal growth factor receptor 2; VEGFR, vascular endothelial growth factor receptor; PD-1, programmed cell death protein-1; RAF, rapidly accelerated fibrosarcoma; PDGFR, platelet-derived growth factor receptor; c-KIT, SCFR, mast/stem cell growth factor receptor; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor; RET, rearranged during transfection; MSI-H, microsatellite instability-high.